Physician profile
Nilsa Leiva
NPI 1114924339
$587.46
in general payments reported to CMS, 2019-2025
14 companies · $27.71 in 2025
The $27.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $16.62 · 2021: $46.59 · 2022: $176 · 2023: $173 · 2024: $46.98 · 2025: $27.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.41 | 2021-2025 | |
| Exact Sciences Corporation | $91.45 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $66.74 | 2019-2022 | |
| Pfizer INC. | $53.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $47.18 | 2020-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $46.00 | 2022-2023 | |
| Abiomed | $30.22 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $27.76 | 2021 | |
| Corium, LLC | $24.14 | 2022 | |
| Sanofi Pasteur INC. | $21.00 | 2019 | |
| Eisai INC. | $17.97 | 2022 | |
| Amarin Pharma, INC. | $15.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.88 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $8.91 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilsa Leiva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.